



PARABOLIC DRUGS LTD.

(An ISO 14001 - 2004 Certified Company)



Ref: PDL:SCY:FEBRUARY:2010-2011/26

Dated: February 2, 2011

The National Stock Exchange of India Limited,
"Exchange Plaza",
Bandra-Kurla Complex,
Bandra (East),
Mumbai (Maharashtra).

SUBJECT : PRESS RELEASE


Dear Sir/Madam,

Please find herewith enclosed Press Release with respect to the performance of the Company during the third quarter/nine months ended on December 31, 2010 along with the major operational highlights during the above said period for your kind perusal.

You are requested to display the same on the Notice Board of your Exchange for the information of members and general public.

Thanking you,

Yours faithfully,
For Parabolic Drugs Limited,


(Anil Kumar)
Company Secretary

Enclosed: As Above.

Regd. Office : S.C.O. 99 - 100, 3rd & 4th Floor, Sector 17 - B,
Chandigarh - 160 017 (India)
Tel. : +91-172-3914646, 3914647 Fax : +91-172-3914645

Corp. Office : 9 AB, Taimoor Nagar, New Friends Colony,
New Delhi (India)
Tel. : +91-11-64510543, 26332660

Works - I : Village Sundhran, P.O. Mubarakpur, Derabassi (Pb.) India
Telefax : (01762) 280305

Works - II : 45, Industrial Area, Phase II, Panchkula (Hry.) India
Tel. : +91-172-2591443

R & D Centre : 280-281, HSIIDC, Tehsil Barwala,
District Panchkula (Hry.) India Tel. : +91-1733-256380

website : www.parabolicdrugs.com



Parabolic Drugs' 9MFY11 net profit up 65.6% to Rs. 37.30 crore

Sales up 24.4% to Rs. 466.04 crore

Parabolic Drugs Limited, a leading research-led API manufacturer and exporter in India, announced the unaudited financial results for the third quarter and nine months ended as on December 31, 2010.

Q3FY11 Performance

- The Company's sales increased by 33.79% to Rs. 164.46 Crores as compared to Rs. 122.93 Crores during Q3FY10
- Net profit was up by 33.2% to Rs. 12.48 Crores as compared to Rs. 9.37 Crores during Q3FY10
- EBITDA increased by 32.35% to Rs. 31.61 Crores as compared to Rs. 23.88 Crores
- On an equity capital of Rs. 61.89 Crores, the fully diluted Earnings per share (EPS) stood at Rs. 2.02


9MFY11 Performance

(9MFY11 – April-December 2010); (9MFY10 – April-December 2009)

- Posted a 24.4% increase in sales to Rs. 466.04 Crores as compared to Rs. 374.52 Crores in 9MFY10, driven by improved exports in regulated markets
- Net profit up 65.6% at Rs. 37.30 Crores as compared to Rs. 22.52 Crores in 9MFY10
- EBITDA increased by 31.9% to Rs. 87.05 Crores as compared to Rs. 66.01 Crores in 9MFY10; EBITDA margin for 9MFY11 was 20.5%, up 140 bps from 9MFY10
- On an equity capital of Rs. 61.89 Crores, the fully diluted Earnings Per Share (EPS) stood at Rs. 6.88

Major operational highlights

During the quarter under review, the Company successfully completed the first phase of its expansion programme initiated in 2008, with the commissioning of Multi-Purpose Plant II in Derabassi, Punjab. MP II is a state-of-the-art unit comprising of 5 manufacturing blocks for parallel production. While, two blocks would be utilized for production of Cephalosporin intermediates, the remaining three will process the finished products. The Company also filed four new Drug Master Files with United States Food and Drugs Administration (USFDA), two Certificate of Suitability



PARABOLIC DRUGS LIMITED

with European Directorate for the Quality of Medicines (EDQM) and four Process Patent Applications for Non-Beta Lactum Products with Indian Patent Office during the quarter. As on date, the total number of DMFs and PPAs filed by the company stood at 26 and 15 respectively (excluding one PCT for international patent).